GleamWall
中文EN

YBGJ Yubo International Biotech Ltd

Electromedical & Electrotherapeutic Apparatus · OTC · SEC CIK 895464 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY68,727.8%
TTM net income YoY31.6%
TTM EPS YoY100.0%
Revenue 3-yr CAGR-73.4%
Net income 3-yr CAGR—

Margins

Gross margin66.1%
Operating margin-8,232.7%
Net margin-7,171.5%
FCF margin—
EBITDA margin-7,667.1%

Returns

ROE—
ROA-110.4%
ROIC (approx.)—
Asset turnover0.02x

Leverage & solvency

Liabilities / assets544.9%
Debt / equity—
Current ratio0.16x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.47x
Accruals ratio-58.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$0$0$12,353$0$0$0-$18
Cost of revenue$0$0$0$4,188$0$0$0-$5
Gross profit$0$0$0$8,165$0$0$0-$13
Operating income-$203,388-$238,860-$289,274-$285,468-$310,134-$249,699-$467,299-$357,298
Interest expense————$18$23——
Pretax income-$203,726-$268,721-$295,026-$285,651-$310,152-$249,722-$467,318-$352,886
Income tax$0$0$0$0$0$0$0$0
Net income-$188,376-$247,949-$272,608-$176,960-$276,771-$230,333-$435,630-$352,886
EBITDA-$202,738-$238,067-$263,529-$242,787-$268,241-$207,955-$425,676-$318,130
EPS (diluted)0.000.000.00—0.000.000.00—
Weighted avg. shares (diluted)170.42M170.42M170.42M—147.87M119.82M119.82M—
Banking
Net interest income——————-$19—
Deposits$74,238$79,207$68,500$71,135$69,792$69,792$68,500$68,500
Balance sheet
Cash & equivalents$9,465$11,989$10,382$8,062$10,926$10,416$9,773$7,015
Receivables$123,473$138,052$134,220$138,043$114,287$118,006$146,687$164,984
Inventory$22,410$24,803$24,414$24,034$37,889$37,650$37,212$36,953
Current assets$579,352$583,098$597,823$667,512$649,563$659,102$685,162$682,751
PP&E, net$17,125$17,444$17,761$43,030$84,645$126,007$165,947$205,911
Intangibles$38,540$39,883$39,175$42,080$43,241$44,653$47,505$50,523
Total assets$651,391$672,272$709,872$847,094$953,211$1.05M$1.17M$1.53M
Current liabilities$3.55M$3.33M$3.02M$2.79M$2.56M$5.03M$4.78M$4.72M
Total liabilities$3.55M$3.33M$3.02M$2.79M$2.56M$5.03M$4.81M$4.83M
Shareholders' equity-$2.85M-$2.62M-$2.30M-$1.95M-$1.66M-$4.00M-$3.67M-$3.42M
Cash flow statement
Operating cash flow-$157-$84,104-$207,157-$128,752-$359,056-$14,028-$392,043-$932,711
Capital expenditure——$0———$6,186—
Free cash flow——-$207,157———-$398,229—
Investing cash flow$0$0$0-$79,904$0$86,090-$6,186$0
Financing cash flow$11,459$77,231$214,523$375,626$0$196,139$277,780$1.11M
Depreciation & amortization$650$793$25,745$42,681$41,893$41,744$41,623$39,168

Free plan shows the latest 8 periods; Pro shows all 70 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.